ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2026
Postoperative acute exacerbations in patients with idiopathic pulmonary fibrosis undergoing lung cancer surgery.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThis study evaluated the incidence, risk factors, and mortality associated with postoperative acute exacerbations in IPF patients undergoing lung cancer surgery.
methodsWe retrospectively reviewed 1,225 lung cancer surgeries performed between 2018-2024, identifying 40 patients meeting ATS/ERS criteria for IPF. Acute exacerbations were defined as new bilateral ground-glass opacities superimposed on preexisting fibrosis within 30 days postoperatively. Clinical, radiological, functional, and pathological data were analyzed using univariate and multivariate logistic regression to identify risk factors for acute exacerbations and mortality.
resultsPostoperative acute exacerbations occurred in 15% (6/40) of patients, with 83.3% mortality within 30 days. Multivariate analysis confirmed lesion size >3cm (OR=3.50, 95%CI: 1.80-6.80, p<0.001), shorter IPF follow-up duration (OR=2.90, 95%CI: 1.50-5.70, p<0.001), and mortality (OR=0.026, 95%CI: 0.001-0.715, P=0.031) as independent risk factors. Overall mortality was 40%, significantly associated with preexisting emphysema (OR=6.998, 95%CI: 1.926-25.449, P=0.003) and long-term oxygen therapy (OR=5.845, 95%CI: 1.475-23.147, P=0.012).
conclusionsPostoperative acute exacerbations are serious complications with high mortality in IPF patients undergoing lung cancer surgery. Tumor characteristics, particularly size and location, should guide preoperative risk assessment and perioperative management strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.